Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis
The BrainGate2 Neural Interface System aims to provide a novel solution for individuals with severe speech impairments, particularly those suffering from conditions like ALS. The potential market includes a significant population of patients with anarthria and dysarthria, representing a niche yet impactful segment within the assistive technology landscape. The competitive landscape includes other neuroprosthetic devices, but the unique focus on speech restoration may offer a distinct advantage. Successful outcomes could lead to partnerships with rehabilitation centers and technology firms, enhancing market penetration. Diligence implications include assessing regulatory pathways and reimbursement strategies, given the unapproved status of the device.
Indication: Anarthria
Modality: medical device
Target: Speech motor cortex neural activity modulation via the BrainGate2 Neural Interface System.
Sponsor: Leigh R. Hochberg, MD, PhD.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Speech motor cortex neural activity modulation via the BrainGate2 Neural Interface System.
View original source fields
Condition raw: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Condition normalized: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Modality raw: medical device
Modality normalized: medical device
Target raw: Speech motor cortex neural activity modulation via the BrainGate2 Neural Interface System.
Target normalized: Speech motor cortex neural activity modulation via the BrainGate2 Neural Interface System.